Welcome subscribers,
The explosive growth of obesity and diabetes medications like Wegovy is transforming healthcare and opening up property investment opportunities across Europe. Read our analysis, along with the latest property transactions, from new builds to acquisitions:
✅ Germany: Kadans invests in Berlin
✅ Ireland: Cork builds more manufacturing space
✅ Netherlands: Deka Immobilien buys logistics asset
✅ UK: Oxford's Clarendon Centre changes hands
Read more below for all the details.
Mega-drugs for weight loss and diabetes are opening new doors in real estate
Pharmaceutical manufacturing is booming but pharma distribution centres are more accessible investment options
Transactions
GERMANY BERLIN
In December 2024, Kadans Science Partner acquired the strategic 9,037 sq m (97,270 sq ft) property at Franklinstraße 8, in Berlin’s Charlottenburg district. This acquisition marks Kadans’ first footprint in Berlin. The project, to be branded Plus Ultra Berlin, will become a multi-tenant lab and office complex with a riverside setting, expected to be delivered in Q2 2028. Working with existing plans from Berlin-based architects Gewers Pudewill, Kadans will adapt the project to include approximately 30,000 sq m (323,920 sq ft) of lab and office space. Partnering with Munich-based Accumulata Group, Kadans aims to leverage Accumulata’s expertise as a service developer for project execution.
NETHERLANDS LEIDEN
ASR Real Estate has purchased Avery Dennison's European headquarters at Leiden Bio Science Park for its ASR Dutch Science Park Fund from LCN Capital Partners. The six-storey building, completed in 2014 and designed by Paul de Ruiter architects, comprises 12,154 sq m (130,825 sq ft) of office and laboratory space. Laboratory and office areas are situated on floors 2 through 5. Avery Dennison, a global materials science company focusing on healthcare applications among other sectors, has been the long-term tenant since the building's completion. The building was originally developed by OVG (now EDGE Technologies). This acquisition, announced in December 2024, expands ASR Dutch Science Park Fund's portfolio.
UK CAMBRIDGE
Mission Street and BentallGreenOak (BGO) are exploring bringing in a strategic investment partner to accelerate the delivery of District East, a 1 million sq ft (92,900 sq m) life sciences scheme in Cambridge, it was reported in November 2024. The project secured planning consent from Cambridge City Council in September 2024. The 23-acre (9.3-hectare) project will include purpose-built laboratory space across seven buildings, along with retail, restaurants, events space and a public square. Located around 10 minutes from the centre of Cambridge, District East is one of the largest projects of its type in the country. BGO and Mission Street acquired the site from Coldham’s Lane in October 2022.